AEOL-10150 (pentachloride)

AEOL-10150 pentachloride is a metalloporphyrin-catalyzed antioxidant and a superoxide dismutase mimetic. AEOL-10150 pentachloride scavenges ROS and RNS, and modulates the NF-κB signaling pathway. AEOL-10150 pentachloride has potent antioxidant and anti-inflammatory activities. AEOL-10150 pentachloride effectively mitigates tissue damage caused by radiation and chemical agents such as CEES (HY-W199190). AEOL-10150 pentachloride synergizes with radiotherapy to exert anticancer effects on prostate tumors^{[1][2][3][4][5][6][7]}. In Vitro:AEOL-10150 (50 μM; 1 h after CEES exposure) pentachloride significantly reverses CEES (HY-W199190)-induced cell viability decline and DNA damage, and reduces cytoplasmic and mitochondrial ROS generation in mouse epidermal JB6 cells, human epidermal HaCaT cells, and normal human epidermal keratinocytes (NHEKs)^[1]. In Vivo:AEOL-10150 (5 mg/kg s.c. + 700 μL topical gel (1 mM); every 4 h for 12 h) pentachloride attenuates skin thickening, microvesication, and DNA oxidation in SKH-1 hairless mice with CEES-induced skin injury^[1].
AEOL-10150 (10-30 mg/kg/day; continuous infusion via subcutaneously implanted osmotic pump; 1-10 weeks) pentachloride significantly reduces pulmonary fibrosis, collagen deposition, and inflammation, and decreases respiratory rate and oxidative stress markers in rats with radiation-induced lung injury^[3].
AEOL-10150 (5 mg/kg; s.c.; administered at 1 and 9 h post-exposure) pentachloride reduces protein, red blood cells, neutrophils, and oxidative stress markers in bronchoalveolar lavage fluid (BALF), improving lung injury in rats with CEES inhalation injury^[5].
AEOL-10150 (6 mg/kg; i.p.; 16 days) pentachloride combined with radiotherapy (10 Gy) inhibits tumor growth more significantly than radiotherapy alone in C57BL/6 mice with RM-9 prostate tumor model^[7].